Peptide Dosage Charts

5-Amino-1MQ is an orally bioavailable NNMT inhibitor studied for adipose tissue modulation and NAD+ preservation. Typically formulated as 50mg or 150mg capsules.

Cagrilintide is a long-acting amylin analogue researched as a standalone satiety modulator and as a partner to Semaglutide (CagriSema). Once-weekly subcutaneous administration.

FOXO4-DRI (FOXO4-D-Retro-Inverso) is a research senolytic peptide studied for selective clearance of senescent cells via disruption of the FOXO4-p53 interaction.

GHK-Cu is a naturally-occurring copper tripeptide studied extensively for skin remodeling, wound repair, and fibroblast activity. Researched via injectable, topical, and intranasal delivery.

GLOW is a researcher-popular blended protocol combining GHK-Cu, BPC-157, and TB-500 into a single subcutaneous injection studied for skin quality, connective tissue recovery, and inflammatory modulation.

MK-677 (Ibutamoren) is an orally-active ghrelin receptor agonist studied as a growth hormone secretagogue. Supports once-daily protocols due to its ~24h half-life.

MOTS-c is a mitochondrial-derived 16-amino-acid peptide studied for metabolic regulation, insulin sensitivity, and mitochondrial resilience.

Selank is a synthetic analogue of tuftsin developed as a nootropic and anxiolytic research peptide, most commonly administered via intranasal spray.

Semaglutide is a long-acting GLP-1 receptor agonist extensively studied for glycemic control and body composition. Once-weekly subcutaneous administration is standard.

Sermorelin is a truncated GHRH analog (GRF 1-29) studied as a GH secretagogue. Short half-life makes evening subcutaneous dosing the typical research pattern.

Tesamorelin is a stabilized GHRH analog with a trans-3-hexenoyl modification that extends plasma half-life relative to Sermorelin. Studied for visceral adiposity and GH axis support.

Retatrutide is a once-weekly triple agonist targeting GLP-1, GIP, and glucagon receptors. The Jastreboff Phase 2 trial (NEJM 2023) reported up to 24.2% mean body-weight reduction at 48 weeks with the 12mg dose, and Lilly's TRIUMPH-4 Phase 3 readout (Dec 11, 2025) confirmed 12mg as the lead dose.

BPC-157 (Body Protection Compound) is a 15-amino-acid pentadecapeptide derived from a sequence in human gastric juice protein. Studied extensively in rodent models for soft-tissue, tendon, and gut-barrier repair (Sikiric et al.). No human randomized controlled trials have been published as of April 2026.

CJC-1295 is a synthetic GHRH analog sold in two distinct forms that dose completely differently. With DAC (drug affinity complex) it binds serum albumin for a 5.8-8.1 day half-life and sustained GH and IGF-1 elevation, characterized in humans by Teichman et al. 2006 (PMID 16352683). Without DAC (modified GRF 1-29) the half-life is roughly 30 minutes, so it is pulsed several times daily and usually paired with a ghrelin agonist such as Ipamorelin (Raun et al. 1998, PMID 9849822).

The CJC-1295 (no DAC) + Ipamorelin pairing is the canonical research GH stack: a short-acting GHRH analog combined with a selective ghrelin receptor agonist. CJC-1295's long-acting DAC form was characterized in humans by Teichman et al. 2006 (PMID 16352683); this pairing instead uses the short-acting no-DAC form (~30 minute half-life). Ipamorelin's selective GH-releasing profile was established in Raun et al. 1998 (PMID 9849822).

PT-141 (bremelanotide) is a melanocortin receptor agonist (primarily MC4R) studied for hypoactive sexual desire disorder. The FDA-approved formulation, Vyleesi, is a 1.75mg subcutaneous autoinjector dosed on demand, supported by the RECONNECT trials (Kingsberg, Clayton et al., Obstetrics & Gynecology 2019, PMID 31033583).

Tirzepatide is a dual GIP and GLP-1 receptor agonist marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022, PMID 35658024) reported mean body-weight reductions of 15.0%, 19.5%, and 20.9% at 5mg, 10mg, and 15mg over 72 weeks.

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that binds cardiolipin on the inner mitochondrial membrane and is studied for restoring mitochondrial bioenergetics. It has been investigated in registered trials for primary mitochondrial myopathy, Barth syndrome, heart failure, and dry AMD, none of which has led to approval. One key point up front: the grey-market research dose (1-5mg per day) sits far below the 40mg per day used in every human trial.

Survodutide (BI 456906) is a once-weekly glucagon receptor and GLP-1 receptor dual agonist from Boehringer Ingelheim, studied for obesity, type 2 diabetes, and MASH. The glucagon arm is intended to add energy expenditure and direct hepatic fat mobilization on top of the appetite and glycemic effects of GLP-1.

GHRP-6 is a hexapeptide ghrelin mimetic (GHS-R1a agonist) studied as a growth-hormone secretagogue. Its signature is strong, ghrelin-like appetite stimulation, which separates it from cleaner secretagogues like ipamorelin. Research protocols cluster at about 100mcg per dose, timed away from food, and it is most often paired with a GHRH analog (CJC-1295 or Mod GRF 1-29) for synergistic GH release.

TB-500 is a synthetic version of the active region of Thymosin Beta-4, an actin-binding peptide studied for cell migration, angiogenesis, and wound, tendon, and muscle repair. Research protocols run a loading phase then a lower maintenance phase, and it is most often paired with BPC-157 for recovery work. Nearly all efficacy data is preclinical.

Melanotan II is a synthetic cyclic melanocortin agonist that activates MC1R (skin pigmentation) plus MC3R, MC4R, and MC5R. It is studied for melanogenesis and, via MC4R, for appetite and sexual arousal. Research protocols use a low-dose loading phase to build pigmentation, then intermittent maintenance. Note the strong side-effect profile and the serious melanoma-monitoring caution below before anything else.

DSIP is a nonapeptide studied since the 1970s for sleep modulation, stress and cortisol reduction, and pain. Be honest about the evidence: it is old and genuinely mixed, DSIP does not reliably induce sleep across studies, and its mechanism is not fully mapped. Research protocols use a small subcutaneous dose before bed.

IGF-1 LR3 is a modified IGF-1 analog with an N-terminal extension and an Arg3 substitution that weaken IGF-binding-protein binding and extend circulation, studied for cell proliferation and muscle. Note two things up front: the 'Long' refers to the peptide extension, not the half-life, and the widely quoted 20-30 hour half-life is vendor lore rather than a clean human PK figure. Hypoglycemia is a real risk.

KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH, studied for anti-inflammatory activity through downregulation of NF-kB and pro-inflammatory cytokine signaling. It is orally active via PepT1 transport, which is why it appears both as an injectable vial and as oral capsules (Dalmasso et al., Gastroenterology 2008).

VIP is a 28-amino-acid neuropeptide with pleiotropic immune, vasoregulatory, and neuroendocrine functions (Delgado & Ganea, Amino Acids 2013). Because its systemic half-life is only a couple of minutes, research protocols almost always use intranasal delivery rather than injection.

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) in the short-peptide bioregulator class studied by Khavinson and colleagues for neuroprotective and neuroregulatory activity in research models. Bioregulators are typically administered in short repeated courses rather than continuously.

AOD-9604 is a modified fragment of the C-terminal region (residues 176-191) of human growth hormone, studied for lipolytic activity without the glucose-related effects of full-length GH. It advanced through obesity trials by Metabolic Pharmaceuticals, though the Phase 2 program did not meet its primary weight endpoint (AOD9604 clinical program, 2000s).

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from a fragment of ACTH(4-10), developed in Russia and studied for nootropic and neuroprotective effects linked to BDNF modulation (Dolotov et al., 2006). The N-acetyl (amidate) variant is more potent per microgram.

Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide bioregulator studied by Khavinson and colleagues for telomerase activation, circadian regulation, and melatonin normalization in research models. Like other bioregulators it is administered in short repeated courses rather than continuously.

LL-37 is the active peptide of the only human cathelicidin, studied for broad antimicrobial activity and immunomodulatory signaling (Vandamme et al., 2012). Research explores both localized and systemic subcutaneous administration.

Thymosin alpha-1 is a 28-amino-acid immunomodulatory peptide. Its pharmaceutical form (Zadaxin) is approved in several countries as an immune modulator and vaccine/antiviral adjunct, dosed subcutaneously (Zadaxin prescribing information; Garaci et al.).

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the helix-B domain of erythropoietin, studied for tissue protection and neuropathic pain without EPO's hematopoietic effects (Brines et al., 2008; sarcoidosis small-fibre neuropathy trials).

Kisspeptin-10 is a truncated fragment of kisspeptin studied for its ability to stimulate GnRH release and downstream LH/FSH secretion, making it a research tool for the reproductive axis (Dhillo et al., 2005). Clinical studies typically use weight-based intravenous dosing.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism, DNA repair, and sirtuin activity. Research and clinic protocols explore subcutaneous micro-dosing and slow intravenous administration for metabolic and longevity contexts.

Melanotan I is an alpha-MSH analogue studied for melanogenesis and photoprotection. Its therapeutic cousin, afamelanotide (Scenesse), is approved for erythropoietic protoporphyria. Melanotan I is more selective than Melanotan II and is associated with fewer off-target effects at comparable tanning exposure.